LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Search

Pfizer

Închisă

SectorSănătate

25.17 0.28

Rezumat

Modificarea prețului

24h

Curent

Minim

25.13

Maxim

25.21

Indicatori cheie

By Trading Economics

Venit

-45M

2.9B

Vânzări

938M

15B

P/E

Medie Sector

13.005

34.427

EPS

0.78

Randament dividend

6.92

Marjă de profit

19.982

Angajați

81,000

EBITDA

266M

5.3B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+13.72% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

6.92%

2.47%

Următoarele câștiguri

28 oct. 2025

Data viitoare de dividende

2 sept. 2025

Următoarea dată ex-dividende

7 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

6B

140B

Deschiderea anterioară

24.89

Închiderea anterioară

25.17

Sentimentul știrilor

By Acuity

52%

48%

294 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Pfizer Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 aug. 2025, 11:34 UTC

Câștiguri

Pfizer Boosts 2025 Adjusted EPS Outlook Following 2Q Gains

5 aug. 2025, 20:44 UTC

Câștiguri

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 aug. 2025, 18:20 UTC

Câștiguri

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5 aug. 2025, 18:17 UTC

Câștiguri

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 aug. 2025, 16:04 UTC

Market Talk

Pfizer's New Tax Rate Helps Boost Adj EPS Outlook -- Market Talk

5 aug. 2025, 15:25 UTC

Câștiguri

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 aug. 2025, 13:56 UTC

Câștiguri

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5 aug. 2025, 11:43 UTC

Câștiguri

Pfizer Stock Pops as Earnings Smash Expectations. Guidance Hiked in Face of Tariffs. -- Barrons.com

5 aug. 2025, 11:27 UTC

Câștiguri

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 aug. 2025, 10:57 UTC

Câștiguri

Pfizer Stock Pops as Earnings Smash Expectations. Why the Outlook Has Been Hiked. -- Barrons.com

5 aug. 2025, 10:55 UTC

Câștiguri

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 aug. 2025, 10:53 UTC

Câștiguri

Pfizer Boosts 2025 Profit Estimate In A Sign Of 'Confidence' -- MarketWatch

5 aug. 2025, 10:51 UTC

Câștiguri

Pfizer: On Track to Deliver About $7.2B Overall Cost Savings From Cost-Improvement Initiatives b/ End of 2027 >PFE

5 aug. 2025, 10:50 UTC

Câștiguri

Pfizer: Expects to Continue to De-Lever in Prudent Manner to Maintain Balanced Capital-Allocation Strategy >PFE

5 aug. 2025, 10:49 UTC

Câștiguri

Pfizer: Current Financial Guidance Doesn't Anticipate Any Share Repurchases in 2025 >PFE

5 aug. 2025, 10:49 UTC

Câștiguri

Pfizer Now Sees 2025 Effective Tax Rate on Adjusted Income About 13%; Had Seen About 15% >PFE

5 aug. 2025, 10:48 UTC

Câștiguri

Pfizer Cuts Adjusted R&D Expenses View to $10.4-$11.4B From $10.7B-$11.7B >PFE

5 aug. 2025, 10:48 UTC

Câștiguri

Pfizer: Guidance Absorbs Impact of Potential Price Changes This Year Based on Letter Received July 31 From President Trump >PFE

5 aug. 2025, 10:47 UTC

Câștiguri

Pfizer: Guidance Absorbs Impact of Currently Imposed Tariffs From China, Canada, Mexico >PFE

5 aug. 2025, 10:46 UTC

Câștiguri

Pfizer Had Seen 2025 Adjusted EPS $2.80-$3.00 >PFE

5 aug. 2025, 10:45 UTC

Câștiguri

Pfizer Raises 2025 EPS Guidance >PFE

5 aug. 2025, 10:45 UTC

Câștiguri

Pfizer 2Q EPS 51c >PFE

5 aug. 2025, 10:45 UTC

Câștiguri

Pfizer Sees FY Adj EPS $2.90-Adj EPS $3.10 >PFE

5 aug. 2025, 10:45 UTC

Câștiguri

Pfizer 2Q Adj EPS 78c >PFE

5 aug. 2025, 10:45 UTC

Câștiguri

Pfizer 2Q Rev $14.7B >PFE

5 aug. 2025, 10:45 UTC

Câștiguri

Pfizer Sees FY Rev $61B-$64B >PFE

4 aug. 2025, 15:26 UTC

Câștiguri

Pfizer Reports Earnings Soon. The Stock Is Slumping for a Reason. -- Barrons.com

30 iul. 2025, 18:36 UTC

Câștiguri

UPS Stock Joins 7% Yielders in S&P 500. Here's Who Else Is in the Club. -- Barrons.com

9 iul. 2025, 09:17 UTC

Acțiuni populare

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

10 iun. 2025, 12:18 UTC

Câștiguri

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

Comparație

Modificare preț

Pfizer Așteptări

Obiectiv de preț

By TipRanks

13.72% sus

Prognoză pe 12 luni

Medie 28.59 USD  13.72%

Maxim 33 USD

Minim 24 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPfizer - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

18 ratings

6

Cumpărare

12

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

22.855 / 23.85Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

294 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.